Pre-market: ZBH.SW Zimmer Biomet (SIX) CHF67.50 04 Feb 2026: RSI 18.8 bounce

ZBH.SW stock opens pre-market at CHF67.50, down -4.26% from the prior close, setting an oversold technical setup ahead of earnings on 10 Feb 2026. The RSI sits at 18.81, well below the 30 oversold threshold, while price trades under the 50‑day and 200‑day averages (78.58 and 87.90). Low intraday volume (110.00) and a year low at CHF67.50 increase the odds of a short-term rebound. Traders should weigh the near-term technical bounce against mixed fundamentals and the upcoming report.

ZBH.SW stock technicals and short-term setup

The immediate technical picture supports an oversold bounce. RSI is 18.81, MACD histogram is -0.32, and ADX reads 53.75, indicating a strong directional move. The stock hit the day low and year low at CHF67.50, creating a clear short-term support level.

A rebound target is plausible toward the 50‑day average at CHF78.58 if volume picks up. Momentum indicators show extreme readings, so any recovery will likely be sharp but short unless earnings or catalysts change trend direction.

ZBH.SW stock fundamentals and valuation

Fundamentals are mixed but not weak. Zimmer Biomet reports EPS CHF3.19 and a trailing PE of 21.16, with a price‑to‑book near 1.35 and free cash flow yield of 7.73%. The company has a current ratio of 2.43 and debt‑to‑equity of 0.64, which supports balance‑sheet stability.

Revenue per share is 40.45 and book value per share is 64.52, placing the current price below book value per share and under the long‑run averages, but earnings growth has slowed recently. These metrics explain why valuation is neutral despite the technical oversold signal.

Meyka grade, forecast and model context for ZBH.SW stock

Meyka AI rates ZBH.SW with a score of 66.74 out of 100 (Grade B, HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. It signals a neutral stance with upside conditional on catalysts.

Meyka AI’s forecast model projects a yearly price of CHF56.70, which implies an estimated downside of -15.93% versus the current CHF67.50. Forecasts are model‑based projections and not guarantees. Shorter horizon monthly and quarterly forecasts sit at CHF51.98 and CHF43.50, underscoring medium‑term downside risk if fundamentals deteriorate.

Catalysts, risks and upcoming events for ZBH.SW stock

The immediate catalyst is the earnings release on 10 Feb 2026, which can trigger volatility and either validate a bounce or extend the downtrend. Guidance and margin commentary will be decisive for investor sentiment.

Risks include slow elective surgery demand in key markets, inventory and supply chain pressure, and a conservative debt profile that leaves limited upside without stronger revenue growth. Positive catalysts include new product uptake in orthopaedics and any margin recovery notes from management.

Trading strategy: oversold bounce approach for ZBH.SW stock

For an oversold bounce strategy, consider a small, staged long position near CHF67.50 with tight stops below CHF66.00 and a first target at CHF75.00. Use volume confirmation above 50‑day average levels before adding size.

A conservative trader should wait for a reclaim of CHF78.58 (50‑day MA) or a bullish reversal in RSI above 30.00. Earnings on 10 Feb 2026 increases short‑term risk; consider trimming into the report or using options to limit downside.

Price targets, peers and sector context

Short‑term bounce target: CHF75.00. Technical recovery target: CHF88.00 (near 200‑day MA at CHF87.90). Downside support remains at CHF67.50 (year low), with a more conservative fair‑value anchor near CHF76.80 (Graham number context).

Healthcare and medical‑devices peers are trading at an average PE near 34.55 for the Swiss healthcare sector, while Zimmer Biomet’s PE near 21.16 suggests relative valuation support if growth returns. For live updates see Meyka ZBH.SW page and earnings calendars on MarketBeat.

Final Thoughts

ZBH.SW stock shows a clear oversold technical setup in the pre‑market at CHF67.50, with RSI 18.81 and sharply negative short‑term momentum. That creates a defined short‑term opportunity for a bounce toward CHF75.00 and, with stronger confirmation, toward the 50‑day average at CHF78.58. However, Meyka AI’s forecast model projects a yearly price of CHF56.70, implying an approximate -15.93% downside versus the current price. Use tight position sizing and confirm any rebound with rising volume or a bullish RSI reversal. Earnings on 10 Feb 2026 is the key catalyst; outcomes there will likely decide whether the bounce becomes a durable recovery or a relief rally. Meyka AI provides this analysis as an AI‑powered market analysis platform; forecasts and grades are model‑based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.